Jeff E. Knight - 15 Jul 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
15 Jul 2024
Net transactions value
-$895,884
Form type
4
Filing time
17 Jul 2024, 17:35:34 UTC
Previous filing
28 Jun 2024
Next filing
26 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $419,626 +17,499 +33% $23.98 70,079 15 Jul 2024 Direct
transaction CRNX Common Stock Options Exercise $57,798 +2,887 +4.1% $20.02 72,966 15 Jul 2024 Direct
transaction CRNX Common Stock Options Exercise $111,693 +5,687 +7.8% $19.64 78,653 15 Jul 2024 Direct
transaction CRNX Common Stock Sale $1,485,000 -27,000 -34% $55.00 51,653 15 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -17,499 -13% $0.000000 112,501 15 Jul 2024 Common Stock 17,499 $23.98 Direct F2
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -2,887 -12% $0.000000 20,213 15 Jul 2024 Common Stock 2,887 $20.02 Direct F3
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -5,687 -6.2% $0.000000 85,313 15 Jul 2024 Common Stock 5,687 $19.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F3 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F4 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.